Mar 24, 2020

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Posted by in categories: biotech/medical, health

SARS-CoV-2 uses the SARS-CoV receptor ACE2 for host cell entry.

The spike protein of SARS-CoV-2 is primed by TMPRSS2.

Antibodies against SARS-CoV spike may offer some protection against SARS-CoV-2.

The emerging SARS-coronavirus 2 (SARS-CoV-2) threatens public health. Hoffmann and coworkers show that SARS-CoV-2 infection depends on the host cell factors ACE2 and TMPRSS2 and can be blocked by a clinically proven protease inhibitor. These findings might help to establish options for prevention and treatment.

Comments are closed.